DEF: Bone Biologics Sets August 11, 2026 Annual Meeting

Bone Biologics Corporation announces its 2026 Annual Meeting of Stockholders to be held on August 11, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Summary

• Bone Biologics Corporation is holding its 2026 Annual Meeting of Stockholders on Tuesday, August 11, 2026, at 11:00 a.m. Eastern Time.
• The meeting will take place at the company's headquarters located at 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803.
• Key agenda items include the election of four directors, an advisory vote on executive officer compensation, and the ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The record date for determining stockholders entitled to vote is June 12, 2026.
• Stockholders can vote via the internet, telephone, by mail with a proxy card, or in person at the meeting.
• The company is utilizing e-proxy rules, sending a Notice of Internet Availability of Proxy Materials on or about July 2, 2026, with the 2025 Annual Report available online.
• A quorum requires at least one-third of the issued and outstanding shares to be represented.
• The Board of Directors unanimously recommends voting FOR the director nominees, executive compensation approval, and the ratification of the accounting firm.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a routine procedural document for an annual meeting with standard governance proposals, but it also highlights significant financial losses and a severe decline in shareholder value.

Positives

• The company is holding its annual meeting to ensure corporate governance and stockholder engagement.
• The Board of Directors is composed entirely of independent directors, fostering objective oversight.
• The company is utilizing e-proxy rules to reduce costs and environmental impact while providing timely access to materials.
• The Audit Committee has determined that the services provided by Weinberg & Company, P.A. are compatible with maintaining their independence.
• The company has adopted a formal code of ethics and an insider trading policy to promote good governance.
• Executive compensation is tied to performance metrics, aligning management interests with company goals.
• Director compensation includes both cash retainers and equity awards, incentivizing long-term commitment.

Negatives

• Two Section 16(a) reports were filed late by Jeffrey Frelick and Deina Walsh, indicating minor compliance lapses.
• The company is in the development stage and is pre-revenue, with significant net losses reported in recent years ($3,108,991 in 2025, $4,112,420 in 2024, $8,948,731 in 2023).
• The value of a $100 investment made at the company's IPO has significantly depreciated to $1.45 by December 31, 2025, reflecting substantial shareholder value erosion.

Risks

• The company is a pre-revenue, development-stage entity focused on a medical device for bone regeneration, indicating inherent risks associated with product development and market entry.
• Litigation, even if not currently material, can have an adverse impact due to defense and settlement costs and diversion of management resources.
• The company's reliance on capital raising efforts is highlighted in executive compensation metrics, suggesting potential future dilution or funding challenges.
• The significant decline in shareholder value, as indicated by the Pay Versus Performance table, poses a risk to investor confidence and future capital raising.

Future Outlook

The filing does not contain specific forward-looking financial guidance but focuses on the upcoming annual meeting agenda and corporate governance matters. Forward-looking statements are qualified by cautionary statements in the Form 10-K.

Management Comments

• "We believe that this process allows us to provide our stockholders with the information they need on a timelier basis, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials."
• "Your vote is important regardless of the number of shares you own."
• "We encourage you to vote promptly."
• "The Board of Directors believe it is important to select the Companys Chairman and Chief Executive Officer in the manner it considers in the best interests of the Company at any given time."
• "Management is responsible for the day-to-day management of risks the Company faces, while the Board of Directors as a whole plays an important role in overseeing the identification, assessment and mitigation of such risks."
• "Our Compensation Committee believes the compensation under the employment agreements and other incentives granted to our named executive officers align our named executive officers interests with those of our stockholders."

Industry Context

StockSavvy.ai notes that this filing is typical for a publicly traded company preparing for its annual shareholder meeting, focusing on director elections, executive compensation, and auditor ratification. The company operates in the life sciences/medical device sector, specifically focusing on bone regeneration, an area with significant R&D investment and regulatory hurdles.

Comparison to Industry Standards

• The company's board composition, with all directors deemed independent, aligns with best practices for corporate governance, particularly for companies listed on major exchanges like Nasdaq.
• The use of e-proxy is a standard practice across the industry, adopted by most public companies to streamline communication and reduce costs.
• The structure of executive compensation, including base salary, performance-based cash awards, and stock options, is consistent with industry norms for development-stage companies, aiming to incentivize management and align interests with shareholders.
• The significant net losses reported are common for pre-revenue biotechnology and medical device companies investing heavily in research and development.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that would individually or collectively have a material adverse effect on its business, results of operations, financial condition, or cash flows.
• However, litigation can still have an adverse impact due to defense and settlement costs, and diversion of management resources.

Related Party Transactions

• The company does not have a formal written policy for reviewing related party transactions and relies on the full Board to review, approve, or ratify such transactions.
• No related party transactions with material interest have occurred since January 1, 2024.

Stakeholder Impact

• Shareholders: The proposals at the meeting directly affect shareholder rights and corporate direction. The significant decline in stock value impacts their investment.
• Management and Employees: Executive compensation is detailed, with performance-based incentives and severance provisions. Stock options are a key component.
• Auditors: The ratification of Weinberg & Company, P.A. as the independent auditor is a key agenda item, impacting financial reporting oversight.
• Board of Directors: The election of directors is a primary focus, ensuring the composition of the governing body.

Next Steps

• Stockholders are urged to vote on the proposals before the Annual Meeting.
• Final voting results will be published in a Form 8-K filing within four business days after the Annual Meeting.
• The company will hold its 2027 Annual Meeting of Stockholders, with deadlines for stockholder proposals and nominations specified.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new operational or financial performance data that would warrant a buy or sell recommendation. While the company's development stage and significant net losses present risks, the focus on governance and the election of directors are standard procedures. Investors should hold their position pending more substantive operational updates or clinical trial results.

Keywords

Bone Biologics Corporation, DEF 14A, Proxy Statement, Annual Meeting, Stockholder Meeting, Board of Directors, Executive Compensation, Independent Auditor, Corporate Governance, Stockholder Vote, SEC Filing